Evidence map›Paper›PMID 40082799›Full record

ArticleBMC pediatrics2025

Evaluation of thrombospondin 1 as a novel biomarker in pediatric-onset systemic lupus erythematosus.

Chenxi Liu, Menglan Zhang, Lingyi Yan, Jie Luo, Zhijun Liu, Ting Liu, Yongmei Jiang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chenxi LiuDepartment of Laboratory Medicine, West China Second University Hospital, Sichuan University, No. 20, Section 3, Renmin Road South, Wuhou District, Chengdu, Sichuan, P.R. China.
Menglan ZhangDepartment of Laboratory Medicine, West China Second University Hospital, Sichuan University, No. 20, Section 3, Renmin Road South, Wuhou District, Chengdu, Sichuan, P.R. China.
Lingyi YanDepartment of Laboratory Medicine, West China Second University Hospital, Sichuan University, No. 20, Section 3, Renmin Road South, Wuhou District, Chengdu, Sichuan, P.R. China.
Jie LuoDepartment of Laboratory Medicine, West China Second University Hospital, Sichuan University, No. 20, Section 3, Renmin Road South, Wuhou District, Chengdu, Sichuan, P.R. China.
Zhijun LiuDepartment of Laboratory Medicine, West China Second University Hospital, Sichuan University, No. 20, Section 3, Renmin Road South, Wuhou District, Chengdu, Sichuan, P.R. China.
Ting LiuDepartment of Laboratory Medicine, West China Second University Hospital, Sichuan University, No. 20, Section 3, Renmin Road South, Wuhou District, Chengdu, Sichuan, P.R. China. liuting88823@163.com.
Yongmei JiangDepartment of Laboratory Medicine, West China Second University Hospital, Sichuan University, No. 20, Section 3, Renmin Road South, Wuhou District, Chengdu, Sichuan, P.R. China. ymj_westchina@163.com.

Funding

Sichuan Science and Technology Program 2023YFS0186Sichuan Science and Technology Program 2023YFS0222
6 · The paper itself

Abstract

objectiveThis study aimed to assess the potential of thrombospondin 1 (TBS-1) as a biomarker for pediatric-onset systemic lupus erythematosus (pSLE) and investigated its association with clinical characteristics and other laboratory tests in pSLE.

methodsA total of 112 pSLE and 50 age-matched and gender-matched healthy controls (HCs) were recruited in this study from January 2022 to June 2023 at West China Second University Hospital, Sichuan university. Plasma TBS-1 levels were measured, and clinical and laboratory findings were collected from the medical database.

resultsThe plasma TBS-1 level was significantly lower in pSLE patients (26778 ng/mL, IQR: 9875-59011) compared to HCs (100583 ng/mL, IQR: 58327-189547) (P < 0.0001). ROC analysis demonstrated that TBS-1 could effectively differentiate pSLE patients and HCs (AUC: 0.845, 95%CI: 0.785-0.905, P < 0.0001) with an optimal cut-off was 49,937 ng/mL, yielding a sensitivity of 84% and specificity of 70.5% based on the Youden index. Compared to TBS-1 positive patients, TBS-1 negative patients exhibited significant reductions in hemoglobin, IgM, and fibrinogen levels.

conclusionIn light of the current data, the efficacy of TBS-1 as a biomarker in pSLE diverged from its performance in adult SLE. In summary, TBS-1 shows potential as a biomarker for pSLE, particularly in hematological manifestations. Further investigations are essential to delve into the immunomodulatory roles of TBS-1 in the autoimmune pathways of pSLE.

Indexed as

Lupus Erythematosus, SystemicThrombospondin 1AdolescentBiomarkersCase-Control StudiesChildFemaleHumansMaleSensitivity and SpecificityBiomarkersThrombospondin 1thrombospondin-1, humanBiomarkerCorrelationPediatric-onset systemic lupus erythematosusThrombospondin 1

Identifiers

PMID40082799
PMCPMC11905435

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.